The race related gene signature demonstrates tumour-specific expression and is validated across independent cohorts. (IMAGE)
Caption
(A) Heatmap showing expression patterns of race-associated differentially expressed genes (FDR <0.050) comparing paired tumour versus non-tumour samples across three independent HCC cohorts: TCGA-LIHC, MONGOLIAN-LC and TIGER-LC. Genes are hierarchically clustered, with expression values displayed as log2 fold changes. Red indicates upregulation in tumour; blue indicates downregulation in tumour. (B) Kaplan-Meier survival curve for NCI-CLARITY discovery cohort stratified by PC-based risk signature (high risk, n=23; low risk, n=23). Risk groups were determined using principal component analysis of survival-associated genes with permutation testing (p=0.001, log rank test). (C) Forest plot showing HRs for the PC-based survival signature across four independent validation cohorts: NCI-CLARITY discovery, TCGA-LIHC, MONGOLIAN-LC and TIGER-LC. Error bars represent 95% CIs. (D) Validation of Module 33 gene signature across multiple cohorts showing HRs with 95% CIs. The module demonstrates consistent prognostic value across NCI-CLARITY, TCGA-LIHC, MONGOLIAN-LC and TIGER-LC cohorts. (E) Tertiary lymphoid structure (TLS) scores by molecular cluster using a 12 chemokine signature. RC2 demonstrates significantly higher TLS scores compared with RC1 (median 7.0 vs 6.1, Mann-Whitney p=0.001). Box plots show median, interquartile range (IQR) and whiskers; each dot represents an individual patient sample. FDR, false discovery rate; HCC, hepatocellular carcinoma; PC, principal component; RC, race-associated clusters.
Credit
By Aryan Neupane, Anuradha Budhu, Farid Rashidi Mehrabadi, et al.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC